

FIG. 1




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D




FIG. 14E




FIG. 15A




FIG. 15B




FIG. 16A




FIG. 16B




FIG. 17A




FIG. 17B




FIG. 18A




FIG. 18B




FIG. 19A




FIG. 19B




FIG. 20A




FIG. 20B




FIG. 21




FIG. 22




FIG. 23





FIG. 24



- Steps: T or NK cells armed with CARs targeting hematologic malignancies
1. Donor T cells or NK cells
 2. Gene disruption or deletion of CD45
 3. Insert of scFv CAR targeting CD45

FIG. 25





FIG. 26



24 well, duplicate, n=3

IL-2 was added at 48hr time point

FIG. 27A




FIG. 27B




FIG. 28A




FIG. 28B




FIG. 29A




FIG. 29B

M GFP CD45CAR




FIG. 30A




FIG. 30B




FIG. 31A




FIG. 31B




FIG. 32A




FIG. 32B




FIG. 32C




FIG. 33A




FIG. 33B




FIG. 33C




FIG. 33D




FIG. 33E




FIG. 33F




FIG. 33G




FIG. 34A




FIG. 34B




FIG. 35A

HEK CD4IL15RA





FIG. 35B

FIG. 36

CD4IL15RA NK cells




FIG. 37
CD4IL15RA T cells




FIG. 38A




FIG. 38B




FIG. 39

CD4 and CD4IL15RA NK CAR cells lyse MOLT4 tumor cells, 1:1




FIG. 40




FIG. 41




FIG. 42




FIG. 43




FIG. 44A




FIG. 44B




FIG. 45

